Essential thrombocythemia
Drug research and approvals for essential thrombocythemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 49 studies of essential thrombocythemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 10 drug trials for it since 2013, and FDA has 7 approved and 6 open orphan designations naming it.
- Recruiting worldwide: 49
- Trials authorized in Canada: 10
- FDA orphan approvals: 7
- EU medicines: 0
Recruiting Now
Newest start dates first, of 49 recruiting on ClinicalTrials.gov ↗- Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With CytopeniasNCT07447817 · Phase 2 · John Mascarenhas · starts Oct 23, 2026
- A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential ThrombocythemiaNCT07623200 · Phase 3 · Incyte Corporation · starts Sep 8, 2026
- A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative NeoplasmsNCT07849231 · Phase 1 · Damora Therapeutics · starts Sep 1, 2026
- A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)NCT07357727 · Phase 3 · Novartis Pharmaceuticals · starts May 27, 2026
- Therapeutic RSK1 Targeting in Myeloid MalignanciesNCT07379125 · Phase 1 · Washington University School of Medicine · starts May 20, 2026
- Study of INCA036978 in Participants With Myeloproliferative NeoplasmsNCT07441694 · Phase 1 · Incyte Corporation · starts May 11, 2026
- Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative NeoplasmNCT07590986 · Not reported · Université Catholique de Louvain · starts May 1, 2026
- A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsNCT07469891 · Phase 1 · Prelude Therapeutics Incorporated · starts Apr 29, 2026
- Safety and Tolerability of ZE74-0282 in Healthy VolunteersNCT07527221 · Phase 1 · Eilean Therapeutics AU Pty Ltd · starts Apr 16, 2026
- Research Platform Myelofibrosis and AnemiaNCT06976918 · Not reported · iOMEDICO AG · starts Feb 19, 2026
Trials Authorized in Canada
Newest first; search them all in Canada trials| Jul 23, 2026 | A phase 3, randomized, open-label study of inca033989 versus best available therapy in participants with essential thrombocythemia and a calr mutation…INCA033989 | Incyte Corporation | Ongoing |
| Jul 12, 2024 | A phase 3, randomized, double-blind, active-comparator-controlled clinical study to evaluate the efficacy and safety of bomedemstat (mk-3543) versus…BOMEDEMSTAT (MK-3543) / HYDROXYUREA | Merck & Co. (MSD) | Ongoing |
| Dec 21, 2023 | A phase 3, randomized, open-label, active-comparator-controlled clinical study to evaluate the safety and efficacy of bomedemstat (mk-3543/img-7289) versus…BOMEDEMSTAT (MK-3543, IMG-7289)/ BUSULFAN | Merck & Co. (MSD) | Ongoing |
| Sep 2, 2022 | A single-arm, multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-ajft (p1101) in adult patients with essential…ROPEGINTERFERON ALFA-2B-NJFT (P1101) | PharmaEssentia | Ongoing |
| Jul 2, 2021 | A phase 3, open-label, multicenter, randomized, active-controlled study to assess pharmacokinetics and compare the efficacy, safety, and tolerability of p1101…P1101 | PharmaEssentia | Ongoing |
| Nov 29, 2019 | A randomized, controlled phase 3 study of pacritinib versus physician's choice in patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or…PACRITINIB (SB1518) / RUXOLITINIB / HYDROXYUREA / DANAZOL | Sobi | Ongoing |
| Feb 28, 2018 | Extended access of momelotinib for subjects with primary myelofibrosis (pmf) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis…MOMELOTINIB | GSK | Closed |
| Jan 10, 2017 | A multicenter phase II, open label, single arm study to evaluate the efficacy and safety of ruxolitinib in the treatment of anemic myelofibrosis patients.JAKAVI (INC424, RUXOLITINIB) | Novartis Pharmaceuticals Corporation | Closed |
| May 9, 2014 | A randomized controlled phase 3 study of oral pacritinib versus best available therapy in patients with thrombocytopenia and primary myelofibrosis,…PACRITINIB (SB1518) | CTI BIOPHARMA CORP | Ongoing |
| Feb 6, 2014 | A phase 3, randomized, double-blind active-controlled study evaluating momelotinib vs. ruxolitinib in subjects with primary myelofibrosis (pmf) or…MOMELOTINIB | Gilead Sciences | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first| Aug 28, 2026 | Besremitreatment of adults with essential thrombocythemia | PharmaEssentia | Approved |
| May 1, 2026 | Jakafi XRtreatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential… | Incyte Corporation | Approved |
| Sep 15, 2023 | Ojjaaratreatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and… | GlaxoSmithKline | Approved |
| Feb 28, 2022 | VonjoTreatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia)… | Sobi, Inc. | Approved |
| Aug 16, 2019 | INREBICINREBIC® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or… | Impact Biomedicines, Inc. a wholly-owned subsidiary of Celgene Corporation | Approved |
| Nov 16, 2011 | JakafiTreatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis… | Incyte Corporation | Approved |
| Mar 14, 1997 | AgrylinTreatment of patients with essential thrombocythemia to reduce the elevated platelet count and the risk of thrombosis and to ameliorate… | Takeda Development Center Americas, Inc. | Approved |
| Nov 2, 2026 | humanized IgG1 bispecific antibody binding to CD3 and…treatment of essential thrombocythemia | Janssen Research & Development, LLC | Designated |
| Jan 1, 2026 | recombinant fully human IgG1 monoclonal antibody…treatment of essential thrombocythemia | mAbTree Biologics AG | Designated |
| Jun 27, 2024 | peginterferon alfa-2aTreatment of essential thrombocythemia (ET) | Pharma& U.S. Inc. | Designated |
| Dec 14, 2020 | Jaktinib Dihydrochloride MonohydrateTreatment of Primary Myelofibrosis (PMF) or Post-polycythemia Vera/Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) | Suzhou Zelgen Biopharmaceuticals Co., Ltd. | Designated |
| Nov 7, 2018 | bomedemstatTreatment of essential thrombocythemia. | Merck & Co., Inc. | Designated |
| Mar 22, 2010 | ruxolitinib phosphateTreatment of essential thrombocythemia | Incyte Corporation | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA